Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1761-1779

  Yallapu, Murali M ^a   Othman, Shadi F ^b   Curtis, Evan T ^b   Bauer, Nichole A ^a   Chauhan, Neeraj ^a,c   Kumar, Deepak ^d,e   Jaggi, Meena ^a,c   Chauhan, Subhash C ^a,c  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

^d UNIVERSITY OF THE DISTRICT OF COLUMBIA   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

Biomedical applications; Cancer therapeutics; Drug delivery systems; Magnetic nanoparticles; Magnetic resonance imaging; Nanomedicine

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CURCUMIN; MAGNETIC NANOPARTICLE; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; MAGNETITE NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RELEASE; ENDOCYTOSIS; HYDRODYNAMICS; IMAGE ANALYSIS; INTERNALIZATION; LIGHT SCATTERING; MAGNETIC FIELD; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; SPECTROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; BREAST TUMOR; FEMALE; HUMAN; METABOLISM; NANOMEDICINE; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CURCUMIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, ELECTRON, TRANSMISSION; NANOMEDICINE; REACTIVE OXYGEN SPECIES;

EID: 84866772589     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29290     Document Type: Article

References (63)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
2. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7(12):683-692.
3. Carey LA. Triple-negative (basal-like) breast cancer: a new entity. Breast Cancer Res. 2007;9(Suppl 1):S13.
4. McGurk R, Fallowfield L, Winters Z. Information provision for patients by breast cancer teams about the side-effects of hormone treatments. Eur J Cancer. 2006;42(12):1760-1767.
5. Sjovall K, Strombeck G, Lofgren A, Bendahl PO, Gunnars B. Adjuvant radiotherapy of women with breast cancer-information, support and side-effects. Eur J Oncol Nurs. 2010;14(2):147-153.
6. Moore S. Managing treatment side effects in advanced breast cancer. Semin Oncol Nurs. 2007;23(4 Suppl 2):S23-S30.
7. Metzger Filho O, Saini KS, Azim HA Jr, Awada A. Prevention and management of major side effects of targeted agents in breast cancer. Crit Rev Oncol Hematol. March 15, 2011. [Epub ahead of print.]
8. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 2008;267(1):133-164.
9. Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G. Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol. 2007;73(7):1024-1032.
10. Hutzen B, Friedman L, Sobo M, et al. Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas. Int J Oncol. 2009;35(4):867-872.
11. Rowe DL, Ozbay T, O'Regan RM, Nahta R. Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin. Breast Cancer (Auckl). 2009;3:61-75.
12. Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 2005;11(20):7490-7498.
13. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010;62(7):919-930.
14. Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res. 2010;3:11.
15. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 2009;11(3): 495-510.
16. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 2012;17(1-2): 71-80.
17. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila). 2011;4(8):1158-1171.
18. Yallapu MM, Dobberpuhl MR, Maher DM, Jaggi M, Chauhan SC. Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr Drug Metab. 2012;13(1):120-128.
19. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci. 2010;351(1):19-29.
20. Yallapu MM, Jaggi M, Chauhan SC. Poly(2-cyclodextrin)/curcumin selfassembly: a novel approach to improve curcumin delivery and its therapeutic efficacy in prostate cancer cells. Macromol Biosci. 2010;10(10): 1141-1151.
21. Yallapu MM, Jaggi M, Chauhan SC. Beta-cyclodextrin-curcumin selfassembly enhances curcumin delivery in prostate cancer cells. Colloids Surf B Biointerfaces. 2010;79(1):113-125.
22. Yallapu MM, Othman SF, Curtis ET, Gupta BK, Jaggi M, Chauhan SC. Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials. 2011;32(7):1890-1905.
23. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007; 4(6):807-818.
24. Laurent S, Bridot JL, Elst LV, Muller RN. Magnetic iron oxide nanoparticles for biomedical applications. Future Med Chem. 2010;2(3): 427-449.
25. Shubayev VI, Pisanic TR II, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev. 2009;61(6):467-477.
26. Yoo D, Lee JH, Shin TH, Cheon J. Theranostic magnetic nanoparticles. Acc Chem Res. 2011;44(10):863-874.
27. Cole AJ, Yang VC, David AE. Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol. 2011;29(7):323-332.
28. Ho D, Sun X, Sun S. Monodisperse magnetic nanoparticles for theranostic applications. Acc Chem Res. 2011;44(10):875-882.
29. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62(11): 1052-1063.
30. Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res. 2011;44(10):842-852.
31. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm. 2005;2(3):194-205.
32. Jain TK, Richey J, Strand M, Leslie-Pelecky DL, Flask CA, Labhasetwar V. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials. 2008; 29(29):4012-4021.
33. Bhattarai SR, Kc RB, Kim SY, et al. N-hexanoyl chitosan stabilized magnetic nanoparticles: implication for cellular labeling and magnetic resonance imaging. J Nanobiotechnology. 2008;6:1.
34. 2 and tat-CLIO. Korean J Radiol. 2007;8(5):365-371.
35. Yallapu MM, Ebeling MC, Chauhan N, Jaggi M, Chauhan SC. Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes. Int J Nanomedicine. 2011;6:2779-2790.
36. Gillis P, Koenig SH. Transverse relaxation of solvent protons induced by magnetized spheres: application to ferritin, erythrocytes, and magnetite. Magn Reson Med. 1987;5(4):323-345.
37. Gupta AK, Naregalkar RR, Vaidya VD, Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine (Lond). 2007;2(1): 23-39.
38. Namdeo M, Saxena S, Tankhiwale R, Bajpai M, Mohan YM, Bajpai SK. Magnetic nanoparticles for drug delivery applications. J Nanosci Nanotechnol. 2008;8(7):3247-3271.
39. Banerjee SS, Chen DH. Cyclodextrin conjugated magnetic colloidal nanoparticles as a nanocarrier for targeted anticancer drug delivery. Nanotechnology. 2008;19(26):265602.
40. Jain TK, Foy SP, Erokwu B, Dimitrijevic S, Flask CA, Labhasetwar V. Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice. Biomaterials. 2009; 30(35):6748-6756.
41. Yallapu MM, Foy SP, Jain TK, Labhasetwar V. PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications. Pharm Res. 2010;27(11):2283-2295.
42. Ly JD, Grubb DR, Lawen A. The mitochondrial membrane potential (deltapsi(m) in apoptosis; an update. Apoptosis. 2003;8(2): 115-128.
43. Manju S, Sreenivasan K. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J Colloid Interface Sci. 2011;359(1):318-325.
44. Manju S, Sreenivasan K. Synthesis and characterization of a cytotoxic cationic polyvinylpyrrolidone-curcumin conjugate. J Pharm Sci. 2011; 100(2):504-511.
45. Marcolino VA, Zanin GM, Durrant LR, Benassi Mde T, Matioli G. Interaction of curcumin and bixin with I-cyclodextrin: complexation methods, stability, and applications in food. J Agric Food Chem. 2011; 59(7):3348-3357.
46. Hegge AB, Schuller RB, Kristensen S, Tonnesen HH. In vitro release of curcumin from vehicles containing alginate and cyclodextrin. Studies of curcumin and curcuminoides. XXXIII. Pharmazie. 2008;63(8): 585-592.
47. Shahani K, Panyam J. Highly loaded, sustained-release microparticles of curcumin for chemoprevention. J Pharm Sci. 2011;100(7): 2599-2609.
48. Utreja P, Jain S, Tiwary AK. Novel drug delivery systems for sustained and targeted delivery of anti-cancer drugs: current status and future prospects. Curr Drug Deliv. 2010;7(2):152-161.
49. Chen W, Xu N, Xu L, et al. Multifunctional magnetoplasmonic nanoparticle assemblies for cancer therapy and diagnostics (theranostics). Macromol Rapid Commun. 2010;31(2):228-236.
50. Bihari P, Vippola M, Schultes S, et al. Optimized dispersion of nanoparticles for biological in vitro and in vivo studies. Part Fibre Toxicol. 2008;5:14.
51. Mahmoudi M, Laurent S, Shokrgozar MA, Hosseinkhani M. Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell "vision" versus physicochemical properties of nanoparticles. ACS Nano. 2011; 5(9):7263-7276.
52. Mahmoudi M, Simchi A, Milani AS, Stroeve P. Cell toxicity of superparamagnetic iron oxide nanoparticles. J Colloid Interface Sci. 2009;336(2):510-518.
53. Fang J, Nakamura H, Iyer AK. Tumor-targeted induction of oxystress for cancer therapy. J Drug Target. 2007;15(7-8):475-486.
54. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004;7(2):97-110.
55. Javvadi P, Segan AT, Tuttle SW, Koumenis C. The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol Pharmacol. 2008;73(5):1491-1501.
56. Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm. 2010;398(1-2):190-203.
57. Acharya S, Sahoo SK. Sustained targeting of Bcr-Abl AAleukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy. Biomaterials. 2011;32(24):5643-5662.
58. Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly(D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm. 2011; 8(3):852-866.
59. Raut SL, Kirthivasan B, Bommana MM, Squillante E, Sadoqi M. The formulation, characterization and in vivo evaluation of a magnetic carrier for brain delivery of NIR dye. Nanotechnology. 2010;21(39):395102.
60. Chertok B, David AE, Yang VC. Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. J Control Release. 2011;155(3): 393-399.
61. Child HW, Del Pino PA, De La Fuente JM, et al. Working together: the combined application of a magnetic field and penetratin for the delivery of magnetic nanoparticles to cells in 3D. ACS Nano. 2011;5(10): 7910-7919.
62. Chen YC, Chang WH, Wang SJ, Hsieh WY. Fluorescent magnetic nanoparticles with specific targeting functions for combinded targeting, optical imaging and magnetic resonance imaging. J Biomater Sci Polym Ed. 2011. [Epub ahead of print.]
63. Shan XH, Hu H, Xiong F, et al. Targeting Glut1-overexpressing MDA-MB-231 cells with 2-deoxy-d-g1ucose modified SPIOs. Eur J Radiol. 2012;81(1):95-99.